Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GSK1904529A (GSK 4529) is a specific inhibitor of IGF-1R (IC50=27 nM) and IR(IC50=25 nM) .
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 8,000 | |||
5 mg | 在庫あり | ¥ 18,000 | |||
10 mg | 在庫あり | ¥ 27,500 | |||
25 mg | 在庫あり | ¥ 45,500 | |||
50 mg | 在庫あり | ¥ 72,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 26,000 |
説明 | GSK1904529A (GSK 4529) is a specific inhibitor of IGF-1R (IC50=27 nM) and IR(IC50=25 nM) . |
ターゲット&IC50 | IGF-1R:27 nM, Insulin receptor:25 nM |
別名 | GSK 4529 |
分子量 | 851.96 |
分子式 | C44H47F2N9O5S |
CAS No. | 1089283-49-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 114 mg/mL (133.8 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GSK1904529A 1089283-49-7 Angiogenesis Apoptosis MAPK Tyrosine Kinase/Adaptors IGF-1R Syk Raf VEGFR Insulin Receptor Inhibitor anti-tumor GSK4529 GSK-1904529A inhibit insulin GSK 4529 GSK-4529 inhibitor